A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-21. Anything still debated is marked as such rather than presented as settled.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
This effect, called the quasispecies model, results in immense variation in any given sample of virus, and gives the opportunity for natural selection to favor viral strains with the highest fitness every time the virus is spread to a new host. Recombination, the joining of two different viral variants, and reassortment, the swapping of viral gene segments among viruses in the same cell, also play a role in resistance, especially in influenza. Antiviral resistance has been reported in antivirals for herpes, HIV, hepatitis B and C, and influenza, but antiviral resistance is a possibility for all viruses. Mechanisms of antiviral resistance vary between virus types.
==== Elicitors ==== Pst DC3000 produces a PsINF1, the INF1 in P. syringae. Hosts respond with autophagy upon detection of this elicitor. Liu et al. 2005 finds this to be the only alternative to mass hypersensitivity leading to mass programmed cell death.
=== Analogues === The closely related medication, methylnaltrexone (N-methylnaltrexone), is used to treat opioid-induced constipation but does not treat addiction as it does not cross the blood–brain barrier. Nalmefene (6-desoxy-6-methylenenaltrexone) is similar to naltrexone and is used for the same purposes as naltrexone. Naltrexone should not be confused with naloxone (N-allylnoroxymorphone), which is used in emergency cases of opioid overdose. Other opioid antagonists related to naltrexone include 6β-naltrexol (6β-hydroxynaltrexone), samidorphan (3-carboxamido-4-hydroxynaltrexone), β-funaltrexamine (naltrexone fumarate methyl ester), nalodeine (N-allylnorcodeine), nalorphine (N-allylnormorphine), and nalbuphine (N-cyclobutylmethyl-14-hydroxydihydronormorphine).
American forces had begun withdrawing from Afghanistan in 2020, under the provisions of a February 2020 US-Taliban agreement that set a May 1, 2021, deadline. The Taliban began an offensive on May 1. By early July, most American troops in Afghanistan had withdrawn. Biden addressed the withdrawal in July, saying, "The likelihood there's going to be the Taliban overrunning everything and owning the whole country is highly unlikely." On August 15, the Afghan government collapsed under the Taliban offensive, and Afghan President Ashraf Ghani fled the country. Biden reacted by ordering 6,000 American troops to assist with evacuating American personnel and Afghan allies. He faced bipartisan criticism for the manner of the withdrawal, with the evacuations described as chaotic and botched. On August 16, Biden addressed the "messy" situation, taking responsibility for it, and admitting that the situation "unfolded more quickly than we had anticipated". He defended his decision to withdraw, saying that Americans should not be "dying in a war that Afghan forces are not willing to fight for themselves". On August 26, a suicide bombing at the Kabul airport killed 13 U.S. service members and 169 Afghans. On August 27, an American drone strike killed two ISIS-K targets, who were "planners and facilitators", according to a U.S. Army general. The U.S. military completed its withdrawal from Afghanistan on August 30. Biden called the extraction of over 120,000 Americans, Afghans, and other allies "an extraordinary success".
Sources: en.wikipedia.org
"Controversy surrounds both the drug study itself and the FDA approval," wrote NEJM editor-at-large Richard P. Wenzel, MD in 2002. The FDA approved the drug despite the advisory committee's split vote (10 to 10) due to concerns about the validity of the claimed efficacy and safety findings on the basis of a single trial. Eli Lilly spokeswoman Judy Kay Moore insisted that the company did not mastermind the ethics task force or steer the guideline-writing process. It was only a coincidence, Moore says, that the ethics task force and the Surviving Sepsis Campaign used the same P.R. firm, Belsito and Company.
==== Illegal marketing of gabapentin for off-label uses settlement (2004) ==== In 1993, the Food and Drug Administration (FDA) approved gabapentin only for treatment of seizures. Warner–Lambert, which merged with Pfizer in 2000, used continuing medical education and medical research, sponsored articles about the drug for the medical literature, and alleged suppression of unfavorable study results, to promote gabapentin. Within five years, the drug was being widely used for off-label uses such as treatment of pain and psychiatric conditions. Warner–Lambert admitted to violating FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses. In 2004, the company paid $430 million in one of the largest settlements to resolve criminal and civil health care liability charges. It was the first off-label promotion case successfully brought under the False Claims Act. A Cochrane review concluded that gabapentin is ineffective in migraine prophylaxis. The American Academy of Neurology rates it as having unproven efficacy, while the Canadian Headache Society and the European Federation of Neurological Societies rate its use as being supported by moderate and low-quality evidence.
=== 2024 Wayanad landslides === In August 2024, the Karnataka government deputed Lad to assist rescue and relief operations in Wayanad, Kerala, following devastating landslides. He camped in the affected area and coordinated with the Kerala government and Karnataka officials concerning people from Karnataka who were stranded or affected.
== Clinical translation == Dextran has yet to be approved for any clinical uses in drug delivery due to a wide variety of limitations including heterogeneity, undesirable side effects, and unknown biological pathways. Changes in the molecular weight of dextran have been shown to alter biological activity, indicating a need for separation and purification processes to ensure batch homogeneity. Dextran, although considered relatively safe and nontoxic in vivo, exhibits a few side effects with the most notable being thrombocytopenia and liver toxicity. The exact biological mechanisms by which dextran-based drug delivery systems act on the drug target must be elucidated as well. Dextran-based drug delivery systems have an enormous potential for clinical use in the treatment of a variety of disease states.
== Clinical significance == At birth, the bones of the skull do not meet. If certain bones of the skull grow too fast, then craniosynostosis (premature closure of the sutures) may occur. This can result in skull deformities. If the lambdoid suture closes too soon on one side, the skull will appear twisted and asymmetrical, a condition called "plagiocephaly". Plagiocephaly refers to the shape and not the condition. The condition is craniosynostosis. The lambdoid suture can be damaged by a fall backward.
Sources: en.wikipedia.org
=== Generalized pressure === Generalized pressure is a physical concept that describes a thermodynamic ensemble of all factors that produce the same volumetric strain in a material. The concept was proposed in a 2022 paper published in Physical Review B by the Lei Li group at Sichuan University. The framework is inspired by the equivalence principle in Einstein's theory of general relativity and aims to unify different sources of volumetric strain. Within this approach, different driving forces—such as chemical pressure and mechanical pressure—can be considered equivalent if they generate the same magnitude of volume strain. Based on a stress–strain model, an equation of state under generalized pressure conditions was derived. The theory was further examined using the ternary semiconductor alloy AlxGa1−xN as a case study. It was reported that the alloy system and its corresponding end-member materials exhibit identical phase-transition points when expressed in terms of generalized pressure.
The "Venus" figurines have been theorized, not universally, as representing a mother goddess; the abundance of such female imagery has inspired the theory that religion and society in Paleolithic (and later Neolithic) cultures were primarily interested in, and may have been directed by, women. Adherents of the theory include archaeologist Marija Gimbutas and feminist scholar Merlin Stone, the author of the 1976 book When God Was a Woman. Other explanations for the purpose of the figurines have been proposed, such as Catherine McCoid and LeRoy McDermott's hypothesis that they were self-portraits of woman artists and R.Dale Gutrie's hypothesis that served as "Stone Age pornography".
=== PDMI === Portable Digital Media Interface (PDMI) is an interconnection between docking stations/display devices and portable media players, which includes 2-lane DisplayPort v1.1a connection. It has been ratified in February 2010 as ANSI/CEA-2017-A.
== Side effects == Side effects of methenamine are minor and infrequent, reportedly occurring in fewer than 4% of individuals. They include dyspepsia (upset stomach), abdominal pain, dysuria (painful or uncomfortable urination), nausea, vomiting, diarrhea, headache, rash, and pruritus (itching). The drug is generally very well-tolerated. Rarely, reversibly elevated liver enzymes, including of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported. Normalization of liver enzymes has occurred with discontinuation or continuation of methenamine. Hypersensitivity reactions have also rarely been reported. It has been said that methenamine, overall, is very safe. Formaldehyde is a known carcinogen, for instance being associated with nasopharyngeal cancer and leukemia. This compound also occurs in small amounts as a contaminant in alcoholic beverages, and is chemically similar to the carcinogenic ethanol (alcohol) metabolite acetaldehyde. Because of the formaldehyde exposure with methenamine, there have been concerns about methenamine's potential carcinogenicity and the possibility that it might increase the risk of cancer, for instance bladder or stomach cancer. No clinical studies have looked directly at the long-term effects of methenamine in this regard. However, there are no published case reports documenting incidence of cancer with methenamine as of 2023. Moreover, animal studies have found no evidence of long-term carcinogenicity with oral methenamine.
== Further reading == Jung, Hans Joachim (2000). Panzer Soldiers for "God, Honor and Fatherland": The History of Panzerregiment Grossdeutschland. Winnipeg, Canada: J. J. Fedorowicz. ISBN 0-921991-51-7. Herbst, Jurgen (2002). Requiem for a German Past: A Boyhood among the Nazis. Madison, Wisconsin: University of Wisconsin Press. ISBN 978-0-299-16414-0. de Lannoy, François; Perrigault, Jean-Claude (1998). La Grossdeutschland: du régiment au Panzerkorps, 1939–1945 [Grossdeutschland: From Regiment to Panzer Corps 1939–1945] (in French). Bayeux, France: Heimdal. ISBN 2-84048-110-3. Lucas, James (1978). Germany's Elite Panzer Force: Grossdeutschland. London: Macdonald and Jane's. ISBN 0-35401-165-0. McGuirl, Thomas; Spezzano, Remy (1997). God, Honor, Fatherland: A Photo History of Panzergrenadier Division Grossdeutschland on the Eastern Front 1942 - 1944. Connecticut: Southbury. ISBN 0-9657584-0-0. Novotny, Alfred (2002). The Good Soldier: From Austrian Social Democracy to Communist Captivity with a Soldier of Panzer-Grenadier Division Grossdeutschland. Bedford, Pennsylvania: Aberjona Press. ISBN 0-966638-99-9. Quarrie, Bruce (1977). Panzer-Grenadier Division Grossdeutschland. London: Osprey Publishing Group. ISBN 0-85045-055-1.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.